Efficacy and Safety of Vibegron Add‐On Therapy for Persistent Overactive Bladder Symptoms in Benign Prostatic Hyperplasia Patients With α 1 ‐Blocker Treatment: A Multi‐Center Prospective Randomized Controlled Study ( VATON Study)
LUTS: Lower Urinary Tract Symptoms · 2026-03 · 18 (2)
DOI: 10.1111/luts.70053 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift LUTS: Lower Urinary Tract Symptoms, online erschienen am 13.03.2026. Verfasst von Masaki Yoshida und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Sakurajyuji Hospital, Kumamoto, Japan. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Prostatic Hyperplasia, Adrenergic alpha-1 Receptor Antagonists, Pyrrolidines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kyorin Pharmaceutical Co. Ltd, Kissei Pharmaceutical Co. Ltd.
Abstract (Originalsprache)
Objectives
To evaluate the efficacy and safety of vibegron add‐on therapy for persistent overactive bladder (OAB) symptoms after α 1 ‐blocker monotherapy for benign prostatic hyperplasia (BPH).
Methods
Eligible patients were aged ≥ 50 years and diagnosed with BPH. All patients had received an α 1 ‐blocker for ≥ 8 weeks, yet had persistent OAB symptoms. Patients were randomized 1:1 to receive add‐on vibegron (50 mg) or to continue α 1 ‐blocker monotherapy. The primary efficacy endpoint was the between‐group difference from baseline (week 0) to week 12 in total overactive bladder symptom score (OABSS). Secondary endpoints included bladder diary parameters, OABSS subscores; International Prostate Symptom Score total, storage/voiding, quality‐of‐life score; and patient satisfaction assessed by the Patient Global Impression. Safety was assessed by recording treatment‐emergent adverse events.
Results
Overall, 158 patients were randomized into two groups ( n = 79 each). The least‐squares mean change in the primary endpoint (OABSS total score) was −1.9 (95% confidence interval [CI]: −2.4 to −1.5) with α 1 ‐blocker monotherapy and −3.3 (95% CI: −3.8 to −2.9) with vibegron add‐on therapy; the between‐group difference was −1.4 (95% CI: −2.0 to −0.8; p < 0.001), indicating a significant improvement with add‐on therapy. Across the secondary endpoints, favorable outcomes were observed. Higher satisfaction was reported in the vibegron add‐on therapy group than in the α 1 ‐blocker monotherapy group. Vibegron was well tolerated, and no serious drug‐related treatment‐emergent adverse events were observed.
Conclusions
Vibegron add‐on therapy to an α 1 ‐blocker may be effective and safe for treating BPH with persistent OAB symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Sakurajyuji Hospital, Kumamoto, Japan.
- Nishino Clinic, Gifu, Japan.
- Nagae Prostate Care Clinic, Shizuoka, Japan.
- Kato Urological Clinic, Kanagawa, Japan.
- Department of Urology, Nakamura Hospital, Oita, Japan.
- Department of Urology, Koga Hospital 21, Fukuoka, Japan.
ORCID-Profile: Makoto Ikeda
Förderung
- Kyorin Pharmaceutical Co. Ltd
- Kissei Pharmaceutical Co. Ltd
Zitieren
APA
Yoshida, M., Nishino, Y., Nagae, H., Kato, S., Sakamoto, S., Hojo, M., Miyauchi, T., Kageyama, S., Takahashi, S., Kuroda, H., Mori, N., Kasagi, Y., Masunaga, K., Nabeshima, Y., Nomiya, M., Iwashita, K., Miyamae, K., Otani, M., Kawahara, K., …, & Haga, N. (2026). Efficacy and Safety of Vibegron Add‐On Therapy for Persistent Overactive Bladder Symptoms in Benign Prostatic Hyperplasia Patients With α 1 ‐Blocker Treatment: A Multi‐Center Prospective Randomized Controlled Study ( VATON Study). LUTS: Lower Urinary Tract Symptoms, 18(2). https://doi.org/10.1111/luts.70053
Vancouver
Yoshida M, Nishino Y, Nagae H, Kato S, Sakamoto S, Hojo M, et al. Efficacy and Safety of Vibegron Add‐On Therapy for Persistent Overactive Bladder Symptoms in Benign Prostatic Hyperplasia Patients With α 1 ‐Blocker Treatment: A Multi‐Center Prospective Randomized Controlled Study ( VATON Study). LUTS: Lower Urinary Tract Symptoms. 2026;18(2). doi:10.1111/luts.70053
BibTeX
@article{Yoshida2026,
author = {Yoshida, Masaki and Nishino, Yoshinori and Nagae, Hiroshi and Kato, Shinobu and Sakamoto, Sadaaki and Hojo, Morifumi and Miyauchi, Toshihide and Kageyama, Shinji and Takahashi, Shinichi and Kuroda, Hideya and Mori, Naoki and Kasagi, Yasuhiro and Masunaga, Koichi and Nabeshima, Yoshiyuki and Nomiya, Masanori and Iwashita, Koichi and Miyamae, Koichi and Otani, Masayuki and Kawahara, Kazuya and Ikeda, Makoto and Kubono, Shinichi and Haga, Nobuhiro},
title = {Efficacy and Safety of Vibegron Add‐On Therapy for Persistent Overactive Bladder Symptoms in Benign Prostatic Hyperplasia Patients With α 1 ‐Blocker Treatment: A Multi‐Center Prospective Randomized Controlled Study ( VATON Study)},
journal = {LUTS: Lower Urinary Tract Symptoms},
year = {2026},
volume = {18},
number = {2},
doi = {10.1111/luts.70053}
}
EUVIMED